Robin Foà, MD, Sapienza University of Rome, Rome, Italy, discusses how patients with Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL) may be able to avoid allogeneic stem cell transplantation. Prof. Foà cites the GIMEMA LAL2116 clinical trial (D-ALBA; NCT02744768), which found that induction with dasatinib followed by infusion with blinatumomab could induce immunomodulation and improved event-free survival (EFS) in patients with Ph+ ALL. To conclude, Prof. Foà highlights the merits and limitations of using measurable residual disease (MRD) as a predictor of patient outcomes, and explains how this tool may be used to guide transplant decisions. This interview took place at the 7th Congress on Controversies in Stem Cell Transplantation and Cellular Therapies (COSTEM) in Berlin, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.